$CLSD
Clearside Biomedical, Inc. Stock $clsd

$clsd Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024030126 Filed on March 12, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$230.0K	$6.345M	$8.226M
YoY Change	5650.0%	1822.73%	519.89%
Cost Of Revenue		$0.00	$355.0K
YoY Change		-100.0%	74.02%
Gross Profit		$6.345M	$7.871M
YoY Change		4935.71%	600.89%
Gross Profit Margin		100.0%	95.68%
Selling, General & Admin	$2.824M	$2.947M	$11.87M
YoY Change	-10.58%	-7.01%	0.84%
% of Gross Profit		46.45%	150.79%
Research & Development	$5.615M	$6.313M	$20.85M
YoY Change	26.15%	25.58%	6.19%
% of Gross Profit		99.5%	264.85%
Depreciation & Amortization	$28.00K	$20.00K	$67.00K
YoY Change	86.67%	-9.09%	-53.79%
% of Gross Profit		0.32%	0.85%
Operating Expenses	$8.439M	$9.260M	$33.07M
YoY Change	10.91%	12.98%	4.64%
Operating Profit	-$8.209M	-$2.915M	-$24.84M
YoY Change	7.94%	-63.88%	-17.94%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$3.902M	-$2.277M	-$9.360M
YoY Change	80.06%	11.51%	180.32%
Pretax Income	-$11.76M	-$4.832M	-$32.49M
YoY Change	26.76%	-49.99%	-1.4%
Income Tax
% Of Pretax Income
Net Earnings	-$11.76M	-$4.832M	-$32.49M
YoY Change	26.76%	-49.99%	-1.4%
Net Earnings / Revenue	-5114.35%	-76.15%	-394.91%
Basic Earnings Per Share	-$0.17		-$0.53
Diluted Earnings Per Share	-$0.17	-$0.08	-$0.53
COMMON SHARES
Basic Shares Outstanding	74.72M	62.41M	61.81M
Diluted Shares Outstanding	69.85M		61.81M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$35.36M	$28.92M	$28.92M
YoY Change	-14.64%	-40.07%	-40.07%
Cash & Equivalents	$35.40M	$28.90M	$28.92M
Short-Term Investments
Other Short-Term Assets	$193.0K	$311.0K	$1.033M
YoY Change	-50.0%	-29.16%	-9.62%
Inventory
Prepaid Expenses	$567.0K	$722.0K
Receivables	$0.00	$170.0K	$170.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$36.12M	$30.12M	$30.12M
YoY Change	-15.16%	-39.02%	-39.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.194M	$2.996M	$3.865M
YoY Change	206.82%	296.82%	106.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$30.00K	$30.00K	$30.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$4.027M	$3.895M	$3.895M
YoY Change	89.24%	104.78%	104.78%
TOTAL ASSETS
Total Short-Term Assets	$36.12M	$30.12M	$30.12M
Total Long-Term Assets	$4.027M	$3.895M	$3.895M
Total Assets	$40.14M	$34.02M	$34.02M
YoY Change	-10.19%	-33.69%	-33.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.363M	$2.205M	$2.205M
YoY Change	-14.49%	110.0%	110.0%
Accrued Expenses	$4.070M	$4.169M	$4.533M
YoY Change	47.79%	-0.24%	0.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.950M	$6.813M	$6.813M
YoY Change	19.38%	17.81%	17.81%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$56.00M	$480.0K	$43.12M
YoY Change	51.31%	-98.63%	23.5%
Total Long-Term Liabilities	$56.00M	$480.0K	$43.12M
YoY Change	51.31%	-98.63%	23.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.950M	$6.813M	$6.813M
Total Long-Term Liabilities	$56.00M	$480.0K	$43.12M
Total Liabilities	$61.95M	$49.93M	$49.93M
YoY Change	47.52%	22.69%	22.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$332.7M	-$320.9M
YoY Change	11.75%	11.26%
Common Stock	$74.00K	$63.00K
YoY Change	21.31%	3.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$21.81M	-$15.91M	-$15.91M
YoY Change
Total Liabilities & Shareholders Equity	$40.14M	$34.02M	$34.02M
YoY Change	-10.19%	-33.69%	-33.69%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$11.76M	-$4.832M	-$32.49M
YoY Change	26.76%	-49.99%	-1.4%
Depreciation, Depletion And Amortization	$28.00K	$20.00K	$67.00K
YoY Change	86.67%	-9.09%	-53.79%
Cash From Operating Activities	-$7.851M	$495.0K	-$18.14M
YoY Change	8.8%	-108.83%	35.69%
INVESTING ACTIVITIES
Capital Expenditures	$57.00K	$120.0K	$1.777M
YoY Change	-50.43%	31.87%	622.36%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$57.00K	-$120.0K	-$1.777M
YoY Change	-50.43%	31.87%	622.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.34M	-257.0K	414.0K
YoY Change	4220.18%	-144.7%	-98.68%
NET CHANGE
Cash From Operating Activities	-7.851M	495.0K	-18.14M
Cash From Investing Activities	-57.00K	-120.0K	-1.777M
Cash From Financing Activities	14.34M	-257.0K	414.0K
Net Change In Cash	6.435M	118.0K	-19.50M
YoY Change	-191.94%	-102.3%	-210.02%
FREE CASH FLOW
Cash From Operating Activities	-$7.851M	$495.0K	-$18.14M
Capital Expenditures	$57.00K	$120.0K	$1.777M
Free Cash Flow	-$7.908M	$375.0K	-$19.91M
YoY Change	7.87%	-106.58%	46.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001539029
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#LicenseMember
CY2022	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#LicenseMember
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#LicenseMember
CY2023Q4	us-gaap	Restricted Cash Asset Statement Of Financial Position Extensible List RestrictedCashAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsCurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37783
CY2023	dei	Entity Registrant Name EntityRegistrantName	Clearside Biomedical, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-2437375
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 North Point Parkway
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Alpharetta
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30005
CY2023	dei	City Area Code CityAreaCode	678
CY2023	dei	Local Phone Number LocalPhoneNumber	270-3631
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	CLSD
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	64000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74721139
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Atlanta, Georgia
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28920000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48258000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	170000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	722000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	704000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	311000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	439000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	30123000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	49401000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2996000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	755000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	869000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1117000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30000
CY2023Q4	us-gaap	Assets Assets	34018000
CY2022Q4	us-gaap	Assets Assets	51303000
CY2023Q4	clsd	Accounts Payable Related Party Current AccountsPayableRelatedPartyCurrent	331000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2205000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1050000
CY2023Q4	clsd	Accrued Liabilities Current Related Party AccruedLiabilitiesCurrentRelatedParty	215000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4169000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4179000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	364000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	349000
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	75000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	205000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6813000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5783000
CY2023Q4	clsd	Liabilities Related To The Sales Of Future Royalties LiabilitiesRelatedToTheSalesOfFutureRoyalties	41988000
CY2022Q4	clsd	Liabilities Related To The Sales Of Future Royalties LiabilitiesRelatedToTheSalesOfFutureRoyalties	33977000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	649000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	936000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	480000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2023Q4	us-gaap	Liabilities Liabilities	49930000
CY2022Q4	us-gaap	Liabilities Liabilities	40696000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62850841
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62850841
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60639827
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60639827
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	63000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	61000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	304948000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	298984000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-320923000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288438000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-15912000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10607000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34018000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	51303000
CY2023	clsd	License And Other Revenue From Related Party LicenseAndOtherRevenueFromRelatedParty	5050000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8226000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1327000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29575000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	355000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	204000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0
CY2023	clsd	Research And Development To Related Party ResearchAndDevelopmentToRelatedParty	1109000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20846000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19630000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18537000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11869000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11770000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11665000
CY2023	us-gaap	Operating Expenses OperatingExpenses	33070000
CY2022	us-gaap	Operating Expenses OperatingExpenses	31604000
CY2021	us-gaap	Operating Expenses OperatingExpenses	30202000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-24844000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-30277000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-627000
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1719000
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	669000
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1003000
CY2023	clsd	Non Cash Interest Expense On Liability Related To Sales Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSalesOfFutureRoyalties	9360000
CY2022	clsd	Non Cash Interest Expense On Liability Related To Sales Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSalesOfFutureRoyalties	3339000
CY2021	clsd	Non Cash Interest Expense On Liability Related To Sales Of Future Royalties NonCashInterestExpenseOnLiabilityRelatedToSalesOfFutureRoyalties	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-32485000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-32947000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	376000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61806959
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60204862
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58491986
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61806959
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60204862
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59906602
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	8763000
CY2021	clsd	Stock Issued During Period Value At Market Sales Agreement StockIssuedDuringPeriodValueAtMarketSalesAgreement	12205000
CY2021	clsd	Issuance Of Common Shares Value Under A Direct Registered Offering IssuanceOfCommonSharesValueUnderADirectRegisteredOffering	11078000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	111000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	388000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5054000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	376000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	37975000
CY2022	clsd	Stock Issued During Period Value At Market Sales Agreement StockIssuedDuringPeriodValueAtMarketSalesAgreement	566000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	112000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4884000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-32947000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	10607000
CY2023	clsd	Stock Issued During Period Value At Market Sales Agreement StockIssuedDuringPeriodValueAtMarketSalesAgreement	1666000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	65000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	33000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4202000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-32485000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-15912000
CY2023	us-gaap	Profit Loss ProfitLoss	-32485000
CY2022	us-gaap	Profit Loss ProfitLoss	-32947000
CY2021	us-gaap	Profit Loss ProfitLoss	376000
CY2023	clsd	Non Cash Interest Expense On Liability Related To The Sales Of Future Royalites NonCashInterestExpenseOnLiabilityRelatedToTheSalesOfFutureRoyalites	9361000
CY2022	clsd	Non Cash Interest Expense On Liability Related To The Sales Of Future Royalites NonCashInterestExpenseOnLiabilityRelatedToTheSalesOfFutureRoyalites	3339000
CY2021	clsd	Non Cash Interest Expense On Liability Related To The Sales Of Future Royalites NonCashInterestExpenseOnLiabilityRelatedToTheSalesOfFutureRoyalites	0
CY2023	us-gaap	Depreciation Depreciation	67000
CY2022	us-gaap	Depreciation Depreciation	145000
CY2021	us-gaap	Depreciation Depreciation	178000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4202000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4884000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	5054000
CY2023	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	55000
CY2021	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-33000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	998000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	220000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-10420000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10869000
CY2023	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-456000
CY2022	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	83000
CY2021	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	155000
CY2023	clsd	Accounts Payable And Accrued Liabilities To A Related Party AccountsPayableAndAccruedLiabilitiesToARelatedParty	82000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	614000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	694000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	681000
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-130000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	205000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5000000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18135000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13365000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10733000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1777000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	246000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1777000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-246000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
CY2023	clsd	Royalty Purchase And Sale Agreement Issuance Costs RoyaltyPurchaseAndSaleAgreementIssuanceCosts	1862000
CY2023	clsd	Proceeds From Royalty Purchase And Sale Agreement Net Of Issuance Costs ProceedsFromRoyaltyPurchaseAndSaleAgreementNetOfIssuanceCosts	0
CY2022	clsd	Proceeds From Royalty Purchase And Sale Agreement Net Of Issuance Costs ProceedsFromRoyaltyPurchaseAndSaleAgreementNetOfIssuanceCosts	-30638000
CY2021	clsd	Proceeds From Royalty Purchase And Sale Agreement Net Of Issuance Costs ProceedsFromRoyaltyPurchaseAndSaleAgreementNetOfIssuanceCosts	0
CY2023	clsd	Paymentstoroyaltypurchaseandsaleagreement Paymentstoroyaltypurchaseandsaleagreement	1350000
CY2022	clsd	Paymentstoroyaltypurchaseandsaleagreement Paymentstoroyaltypurchaseandsaleagreement	0
CY2021	clsd	Paymentstoroyaltypurchaseandsaleagreement Paymentstoroyaltypurchaseandsaleagreement	0
CY2023	clsd	Proceeds From Issuance At The Market ProceedsFromIssuanceAtTheMarket	1666000
CY2022	clsd	Proceeds From Issuance At The Market ProceedsFromIssuanceAtTheMarket	566000
CY2021	clsd	Proceeds From Issuance At The Market ProceedsFromIssuanceAtTheMarket	12205000
CY2023	clsd	Proceeds From Registered Direct Offering Net Of Issuance Costs ProceedsFromRegisteredDirectOfferingNetOfIssuanceCosts	0
CY2022	clsd	Proceeds From Registered Direct Offering Net Of Issuance Costs ProceedsFromRegisteredDirectOfferingNetOfIssuanceCosts	0
CY2021	clsd	Proceeds From Registered Direct Offering Net Of Issuance Costs ProceedsFromRegisteredDirectOfferingNetOfIssuanceCosts	11078000
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	65000
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	112000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	111000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	33000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	388000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	414000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31333000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23782000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19498000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17722000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13049000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	48418000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	30696000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17647000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28920000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	48418000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	30696000
CY2023	clsd	Purchase Of Property And Equipment Included In Accrued Liabilities PurchaseOfPropertyAndEquipmentIncludedInAccruedLiabilities	531000
CY2022	clsd	Purchase Of Property And Equipment Included In Accrued Liabilities PurchaseOfPropertyAndEquipmentIncludedInAccruedLiabilities	282000
CY2021	clsd	Purchase Of Property And Equipment Included In Accrued Liabilities PurchaseOfPropertyAndEquipmentIncludedInAccruedLiabilities	0
CY2023	clsd	Forgiveness Of Paycheck Protection Program Loan And Accrued Interest ForgivenessOfPaycheckProtectionProgramLoanAndAccruedInterest	0
CY2022	clsd	Forgiveness Of Paycheck Protection Program Loan And Accrued Interest ForgivenessOfPaycheckProtectionProgramLoanAndAccruedInterest	0
CY2021	clsd	Forgiveness Of Paycheck Protection Program Loan And Accrued Interest ForgivenessOfPaycheckProtectionProgramLoanAndAccruedInterest	998000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28920000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48258000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30436000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	160000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	0
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	160000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	260000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28920000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	48418000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	30696000
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2011-05-26
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28900000
CY2024Q1	clsd	Proceeds From Registered Direct Offering ProceedsFromRegisteredDirectOffering	13900000
CY2023Q4	clsd	Maintance Fees Operating License Liability Payments Remainder Of Fiscal Year MaintanceFeesOperatingLicenseLiabilityPaymentsRemainderOfFiscalYear	250000
CY2023Q4	clsd	Maintenance Fee Operating License Liability Payments Due Next Twelve Months MaintenanceFeeOperatingLicenseLiabilityPaymentsDueNextTwelveMonths	250000
CY2023Q4	clsd	Maintenance Fee Operating License Liability Payments Due Year Two MaintenanceFeeOperatingLicenseLiabilityPaymentsDueYearTwo	250000
CY2023Q4	clsd	Maintenance Fee Operating License Liability Payments Due Year Three MaintenanceFeeOperatingLicenseLiabilityPaymentsDueYearThree	350000
CY2023Q4	clsd	Maintenance Fee Operating License Liability Payments Due Year Four MaintenanceFeeOperatingLicenseLiabilityPaymentsDueYearFour	400000
CY2023Q4	clsd	Maintenance Fee Operating License Liability Payments Due Year Five MaintenanceFeeOperatingLicenseLiabilityPaymentsDueYearFive	500000
CY2022Q4	clsd	Initial Proceeds From Royalty Sale And Purchase Agreement Net Of Certain Expenses InitialProceedsFromRoyaltySaleAndPurchaseAgreementNetOfCertainExpenses	32100000
CY2022	clsd	Initial Proceeds From Royalty Purchase And Sale Agreement InitialProceedsFromRoyaltyPurchaseAndSaleAgreement	32500000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include the estimate of the total amount of future royalty revenue and milestone payments to be generated over the life of the Purchase and Sale Agreement, revenue recognition, the accounting for useful lives to calculate depreciation and amortization, clinical trial expense accruals, share-based compensation expense and income tax valuation allowance. Actual results could differ from these estimates.</span></p>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk Arising From Cash Deposits in Excess of Insured Limits</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains its cash in bank deposits that at times may exceed federally insured limits. The Company has not experienced any loss in such accounts. The Company believes it is not exposed to any significant risks with respect to its cash balances.</span></p>
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3916000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1608000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	920000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	853000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2996000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	755000
CY2023Q4	clsd	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	2078000
CY2022Q4	clsd	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	1817000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1862000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1837000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	38000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	49000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	191000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	476000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4169000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4179000
CY2022	clsd	Initial Proceeds From Royalty Purchase And Sales Agreement InitialProceedsFromRoyaltyPurchaseAndSalesAgreement	32500000
CY2023	clsd	Purchase And Sale Agreement Description PurchaseAndSaleAgreementDescription	The Purchase and Sale Agreement will automatically expire, and the payment of Royalties from the Royalty Sub to HCR will cease, when HCR has received payments of the Royalties equal to 2.5 times the aggregate amount of payments made by HCR under the Agreement if the Second Milestone Event is achieved on or prior to December 31, 2024 (the “Initial Cap”). If the Second Milestone Event is not achieved on or prior to December 31, 2024, payment of Royalties from Royalty Sub to HCR will cease when HCR has received Royalties payments equal to 3.4 times the aggregate amount of payments under the Purchase and Sale Agreement (the “Alternative Cap”, and together with the Initial Cap, the “Cap Amount”). In the event of a change in control, acquiror will have the option to make a payment to HCR of the Cap Amount then in effect, less the aggregate amount of Royalty payments made by Royalty Sub to HCR under the Purchase and Sale Agreement as a one-time payment at which time, payment of Royalties to HCR will cease. Alternatively, in the event of a change in control, the acquiror will have the option to make an initial payment of 1.0 times the aggregate amount of payments made by HCR under the Purchase and Sale Agreement as of the date of such change in control, then in that event, payment of Royalties from Royalty Sub to HCR will cease when HCR has received total Royalties payments (including the initial payment) equal to the Alternative Cap. After the Purchase and Sale Agreement expires, all rights to receive the Royalties return to Royalty Sub.On December 22, 2023, the Company, through its wholly owned subsidiary Royalty Sub, entered into the Letter Agreement with the Agent amending that certain Purchase and Sale Agreement, dated as of August 8, 2022, by and among Royalty Sub, HCR and Agent. Pursuant to the terms of the Letter Agreement, Royalty Sub and Agent mutually agreed that Royalty Sub waived any and all rights to the First Milestone Payment in connection with the closing of the transactions contemplated by the Purchase and Sale Agreement and agreed to the release of the First Milestone Payment to Agent.
CY2022	clsd	Debt Related Commitment Fees And Debt Related Issuance Costs DebtRelatedCommitmentFeesAndDebtRelatedIssuanceCosts	1900000
CY2023	clsd	Initial Proceeds From Royalty Purchase And Sale Agreement InitialProceedsFromRoyaltyPurchaseAndSaleAgreement	33977000
CY2023	clsd	Paymentstoroyaltypurchaseandsaleagreement Paymentstoroyaltypurchaseandsaleagreement	1350000
CY2023	clsd	Non Cash Interest Expense On Liability Related To The Sales Of Future Royalites NonCashInterestExpenseOnLiabilityRelatedToTheSalesOfFutureRoyalites	9361000
CY2023Q4	clsd	Liabilities Related To The Sales Of Future Royalties LiabilitiesRelatedToTheSalesOfFutureRoyalties	41988000
CY2023Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.233
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62850841
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-2.5397
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60639827
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y9M
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52657000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	50267000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	53966000
CY2023Q4	clsd	Deferred Tax Assets Tax Non Deductible Accruals Accrued Expenses DeferredTaxAssetsTaxNonDeductibleAccrualsAccruedExpenses	562000
CY2022Q4	clsd	Deferred Tax Assets Tax Non Deductible Accruals Accrued Expenses DeferredTaxAssetsTaxNonDeductibleAccrualsAccruedExpenses	386000
CY2021Q4	clsd	Deferred Tax Assets Tax Non Deductible Accruals Accrued Expenses DeferredTaxAssetsTaxNonDeductibleAccrualsAccruedExpenses	469000
CY2023Q4	clsd	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	210000
CY2022Q4	clsd	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	238000
CY2021Q4	clsd	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	96000
CY2023Q4	clsd	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	246000
CY2022Q4	clsd	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	274000
CY2021Q4	clsd	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	176000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3339000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2678000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2768000
CY2023Q4	clsd	Deferred Tax Liabilities Depreciation Differences DeferredTaxLiabilitiesDepreciationDifferences	71000
CY2022Q4	clsd	Deferred Tax Liabilities Depreciation Differences DeferredTaxLiabilitiesDepreciationDifferences	40000
CY2021Q4	clsd	Deferred Tax Liabilities Depreciation Differences DeferredTaxLiabilitiesDepreciationDifferences	44000
CY2023Q4	clsd	Royalty Purchases And Sale Agreement RoyaltyPurchasesAndSaleAgreement	10495000
CY2022Q4	clsd	Royalty Purchases And Sale Agreement RoyaltyPurchasesAndSaleAgreement	7247000
CY2021Q4	clsd	Royalty Purchases And Sale Agreement RoyaltyPurchasesAndSaleAgreement	0
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5777000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3057000
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	84045000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	73699000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66599000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	6000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0859
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0085
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-5.9932
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0144
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0134
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0315
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0364
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0218
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3185
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2157
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	8.4782
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.0319
CY2023	clsd	Adjustment To Prior Year Tax Provision AdjustmentToPriorYearTaxProvision	0
CY2022	clsd	Adjustment To Prior Year Tax Provision AdjustmentToPriorYearTaxProvision	0.0067
CY2021	clsd	Adjustment To Prior Year Tax Provision AdjustmentToPriorYearTaxProvision	-0.13
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.0006
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.0009
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.0397
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	84000000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7520000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7520000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7520000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7520000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	7500000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	7500000
CY2021	clsd	Unrecognized Tax Expenses UnrecognizedTaxExpenses	48000
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0
CY2023	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Ownership changes, as defined by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), may limit the amount of net operating losses that a company may utilize to offset future taxable income and taxes payable. In general, if the Company experiences a greater than 50% aggregate change in ownership over a 3-year period (a Section 382 ownership change), utilization of the Company’s pre-change NOL carryforwards may be subject to limitation under the Code. The annual limitation generally is determined by multiplying the value of the Company’s stock at the time of such ownership change (subject to certain adjustments) by the applicable long-term tax-exempt rate for the month in which the ownership change occurred. Such limitation may result in expiration of a portion of the NOL carryforwards before utilization. The Company has completed an owner shift analysis to determine the dates in which the Company may have experienced a Section 382 ownership change, and determined that the Company experienced ownership changes for Section 382 purposes in January 2012, December 2013, and July 2016.
CY2023Q4	clsd	Deferred Tax Assets Operating Losses Carryforwards Domestic DeferredTaxAssetsOperatingLossesCarryforwardsDomestic	38000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2000
CY2023	clsd	Schedule Of Operating Leases Assets And Liabilities ScheduleOfOperatingLeasesAssetsAndLiabilities	<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s operating leases included on the balance sheet are as follows (in thousands):</span> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:81.56%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:15.44%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, <br/>2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use asset</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">869</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Liabilities</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current portion of operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">364</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">649</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liabilities</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,013</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	869000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	364000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	649000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1013000
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	The renewal option is not included in the calculation of the right-of-use asset and the lease liabilities as the Company is not reasonably certain if the Alpharetta, Georgia lease will be renewed.
CY2023Q4	clsd	Incremental Borrowing Rate IncrementalBorrowingRate	0.08
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	362000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	339000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	392000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	378000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	389000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	367000
CY2023Q4	clsd	Operating Leases Future Minimum Payment Due OperatingLeasesFutureMinimumPaymentDue	1134000
CY2023Q4	clsd	Operating Lease Imputed Interest OperatingLeaseImputedInterest	121000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1013000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	339000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	262000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	247000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	19000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	87000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	95000
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	93000
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	86000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	12000
CY2023Q4	clsd	Maintenance Fee Payments Due Next Rolling Twelve Months MaintenanceFeePaymentsDueNextRollingTwelveMonths	250000
CY2023Q4	clsd	Maintenance Fee Payments Due In Rolling Year Two MaintenanceFeePaymentsDueInRollingYearTwo	250000
CY2023Q4	clsd	Maintenance Fee Payments Due In Rolling Year Three MaintenanceFeePaymentsDueInRollingYearThree	350000
CY2023Q4	clsd	Maintenance Fee Payments Due In Rolling Year Four MaintenanceFeePaymentsDueInRollingYearFour	400000
CY2023Q4	clsd	Maintenance Fee Payments Due In Rolling Year Five MaintenanceFeePaymentsDueInRollingYearFive	500000
CY2023Q4	clsd	Maintenance Fee Payments Due MaintenanceFeePaymentsDue	1750000
CY2023Q4	clsd	Maintenance Fee Payments Remainder Of Fiscal Year MaintenanceFeePaymentsRemainderOfFiscalYear	250000
CY2023Q4	clsd	Maintenance Fee Payments Due Next Rolling Twelve Months MaintenanceFeePaymentsDueNextRollingTwelveMonths	250000
CY2023Q4	clsd	Maintenance Fee Payments Due In Rolling Year Two MaintenanceFeePaymentsDueInRollingYearTwo	250000
CY2023Q4	clsd	Maintenance Fee Payments Due In Rolling Year Three MaintenanceFeePaymentsDueInRollingYearThree	350000
CY2023Q4	clsd	Maintenance Fee Payments Due In Rolling Year Four MaintenanceFeePaymentsDueInRollingYearFour	400000
CY2023Q4	clsd	Maintenance Fee Payments Due In Rolling Year Five MaintenanceFeePaymentsDueInRollingYearFive	500000
CY2023Q4	clsd	Fair Value Assets Between Level1 Level2 And Level3 Transfers Amount FairValueAssetsBetweenLevel1Level2AndLevel3TransfersAmount	0
CY2022Q4	clsd	Fair Value Assets Between Level1 Level2 And Level3 Transfers Amount FairValueAssetsBetweenLevel1Level2AndLevel3TransfersAmount	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-32485000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-32947000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	376000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61806959
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60204862
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58491986
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61806959
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60204862
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59906602
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10730465
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8408058
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5708394

Files In Submission

Name	View Source	Status
0000950170-24-030126-index-headers.html	Edgar Link	pending
0000950170-24-030126-index.html	Edgar Link	pending
0000950170-24-030126.txt	Edgar Link	pending
0000950170-24-030126-xbrl.zip	Edgar Link	pending
clsd-20231231.htm	Edgar Link	pending
clsd-20231231.xsd	Edgar Link	pending
clsd-ex10_31.htm	Edgar Link	pending
clsd-ex10_33.htm	Edgar Link	pending
clsd-ex10_35.htm	Edgar Link	pending
clsd-ex23_1.htm	Edgar Link	pending
clsd-ex31_1.htm	Edgar Link	pending
clsd-ex31_2.htm	Edgar Link	pending
clsd-ex32_1.htm	Edgar Link	pending
clsd-ex97_clawbackpo.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img141503921_0.jpg	Edgar Link	pending
img141503921_1.jpg	Edgar Link	pending
img141503921_2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
clsd-20231231_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLSD
Clearside Biomedical, Inc. Stock $clsd

2024 Q1 Form 10-K Financial Statement

#000095017024030126 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLSD Clearside Biomedical, Inc. Stock $clsd

2024 Q1 Form 10-K Financial Statement

#000095017024030126 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLSD
Clearside Biomedical, Inc. Stock $clsd